Boston, MA — October 14, 2025 — Leads & Copy — Benchling has launched Benchling AI and other capabilities designed to automate R&D workflows and integrate AI into daily scientific tasks. The announcement was made at Benchtalk, Benchling’s annual customer conference.
Benchling AI aims to provide a command center for scientific AI, allowing scientists to analyze results and generate reports more efficiently. The platform integrates with NVIDIA NIM microservices and includes a partnership with GXL to develop domain-specific expert agents.
The company also announced advancements in antibody discovery, automation, and development, including a unified biologics solution following the acquisition of PipeBio. This integrates PipeBio’s sequence analysis tools with Benchling’s biologics registry. New custom code capabilities enable scientists to run Python and R scripts within Benchling, enhancing data transformation and visualization. The platform now supports process characterization and analytical method development.
Sajith Wickramasekara, CEO and co-founder of Benchling, stated that the company’s mission is to accelerate the development of life-saving medicines through advancements in AI. Ashu Singhal, President and co-founder of Benchling, highlighted the increased efficiency scientists gain by embedding AI directly into their workflows.
Shawna Wolverton, Chief Product Officer at Benchling, emphasized the importance of bringing discovery and development closer together to improve decision-making and scale science.
Contact: press@benchling.com
Source: Benchling
